Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Systemic Sclerosis-Related Interstitial Lung Disease (LOTUSS)
NCT01933334Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pirfenidone in Systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by Genentech. Started Oct 2013; status: completed.
02
Drugs
pirfenidone
03
Conditions
Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT01933334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933334.